viewAmryt Pharma PLC

Amryt Pharma boss 'really pleased' with FY results, on 18.5% increase in revenue year-over-year

Amryt Pharma PLC (LON:AMYT) (NASDAQ:AMYT) CEO Joey Wiley tells Proactive it expects to continue strong sales growth for 2021 after reporting a first underlying profit and strong cash flow for the past year.

Wiley says the biopharma company, which acquires, develops and commercializes novel treatments for rare diseases, generated revenue growth of 18.5% to US$182.6M for 2020 from its two products on the market, metreleptin as a supplement for people with leptin deficiency and lomitapide, for adults with a rare cholesterol disorder.

Quick facts: Amryt Pharma PLC

Price: 205 GBX

Market: AIM
Market Cap: £367.12 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...


Market Report: FTSE falls as Deliveroo fails to deliver on listing debut

FTSE 100 slipped back after US stocks were pressured by rising treasury yields and inflation concerns. London’s leading index shed 16 points to 6,744 in early dealings with a dismal start to trading by Deliveroo also dampening the mood.   Having been priced at 390p, the bottom of its...

1 week, 5 days ago

2 min read